Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$30.98
neg -0.52
-1.70%
Today's Range: 30.72 - 31.69 | MYL Avg Daily Volume: 6,360,600
Last Update: 09/19/17 - 3:59 PM EDT
Volume: 7,100,082
YTD Performance: -17.43%
Open: $31.52
Previous Close: $31.50
52 Week Range: $37.59 - $67.34
Oustanding Shares: 536,280,738
Market Cap: 17,177,072,038
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 6 6
Moderate Buy 0 0 0 0
Hold 7 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 1.92 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 25.83
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
25.83 18.80 36.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-14.22% -24.62% -34.96%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $1.20 $1.31 $4.58 $5.12
Number of Analysts 5 5 7 7
High Estimate $1.31 $1.37 $4.67 $5.41
Low Estimate $1.10 $1.25 $4.44 $4.75
Prior Year $1.38 $1.57 $4.89 $4.58
Growth Rate (Year over Year) -12.90% -16.82% -6.43% 11.80%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Sep 13, 2017 | 11:30 AM EDT
Answering questions from the biotech mailbag.
By

Bruce Kamich

 | Sep 12, 2017 | 11:34 AM EDT
A retest of MYL's recent low is an important area.

bearishArgus Cuts Mylan to Hold

Aug 22, 2017 | 9:00 AM EDT
Mylan was downgraded to "Hold" from "Buy" at Argus

bullishCiti Raises Mylan to Buy

Aug 16, 2017 | 9:05 AM EDT
Mylan was upgraded at Citi to "Buy" from "Neutral" with a $42 price target.
RMPIA
By

Jim Cramer

 | Aug 9, 2017 | 11:36 AM EDT
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
RMPIA
By

Bob Byrne

 | Aug 7, 2017 | 7:00 AM EDT
I would look to begin trading it on the long side above $160.

updateCantor Initiates Mylan at Neutral

Jun 16, 2017 | 9:26 AM EDT
Cantor Fitzgerald has initiated coverage of Mylan with a "Neutral" rating.
By

Bruce Kamich

 | May 1, 2017 | 12:18 PM EDT
It looks like the stock is trying to rebase again.
RMPIA
By

Jim Cramer

 | Mar 7, 2017 | 2:00 PM EST
Drug companies are the latest targets/beneficiaries.
By

Jim Cramer

 | Feb 28, 2017 | 11:30 AM EST
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
BBY is getting smoked this mornings(weak forecast).  The stock is off 8% after openin...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.